Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$131.95 +3.1%	$129.84	$110.04 ▼ $213.50	$18.76B	0.13	1.27 million shs	2.80 million shs
INCY Incyte	$75.59 +0.9%	$68.95	$53.56 ▼ $83.95	$14.62B	0.71	1.60 million shs	1.58 million shs
MNTA Momenta Pharmaceuticals	$52.48	$52.44	$12.21 ▼ $52.53	$6.25B	1.71	1.94 million shs	N/A
UTHR United Therapeutics	$294.28 +7.1%	$298.13	$266.98 ▼ $417.82	$12.39B	0.57	426,182 shs	2.43 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	+3.09%	+0.33%	-0.93%	+6.82%	-38.11%
INCY Incyte	+0.93%	+7.68%	+10.88%	+20.89%	+16.17%
MNTA Momenta Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
UTHR United Therapeutics	+7.13%	-3.36%	-0.32%	-0.11%	-6.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.8487 of 5 stars	4.2	4.0	0.0	3.7	3.3	2.5	1.9
INCY Incyte	4.7569 of 5 stars	2.1	4.0	0.0	2.8	3.2	3.3	4.4
MNTA Momenta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	4.9608 of 5 stars	4.3	3.0	0.0	4.6	3.8	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.34	Hold	$185.63	40.68% Upside
INCY Incyte	2.28	Hold	$79.73	5.48% Upside
MNTA Momenta Pharmaceuticals	0.00	N/A	N/A	N/A
UTHR United Therapeutics	2.69	Moderate Buy	$379.69	29.02% Upside

Current Analyst Ratings Breakdown

Latest MNTA, BIIB, INCY, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/1/2025	BIIB Biogen	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$125.00 ➝ $135.00
8/1/2025	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$208.00 ➝ $219.00
8/1/2025	BIIB Biogen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$146.00 ➝ $144.00
8/1/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$187.00 ➝ $194.00
8/1/2025	INCY Incyte	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$90.00
7/31/2025	UTHR United Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$425.00 ➝ $400.00
7/31/2025	UTHR United Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$314.00 ➝ $295.00
7/30/2025	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$88.00 ➝ $103.00
7/30/2025	INCY Incyte	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform	$52.00 ➝ $60.00
7/30/2025	INCY Incyte	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$73.00 ➝ $79.00
7/30/2025	INCY Incyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$62.00 ➝ $68.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.68B	2.00	$23.82 per share	5.54	$120.35 per share	1.10
INCY Incyte	$4.24B	3.48	$0.56 per share	135.28	$21.36 per share	3.54
MNTA Momenta Pharmaceuticals	$23.87M	261.69	N/A	N/A	$4.59 per share	11.43
UTHR United Therapeutics	$2.88B	4.61	$30.43 per share	9.67	$159.04 per share	1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$10.13	12.61	7.99	1.85	15.31%	13.85%	8.32%	N/A
INCY Incyte	$32.62M	$4.40	17.18	11.56	0.62	18.99%	21.99%	14.43%	N/A
MNTA Momenta Pharmaceuticals	-$290.05M	-$3.03	N/A	N/A	N/A	-757.61%	-61.44%	-45.28%	N/A
UTHR United Therapeutics	$1.20B	$25.06	11.49	10.70	5.97	40.36%	18.73%	16.49%	N/A

Latest MNTA, BIIB, INCY, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/31/2025	Q2 2025	BIIB Biogen	$3.93	$5.47	+$1.54	$4.33	$2.32 billion	$2.65 billion
7/30/2025	Q2 2025	UTHR United Therapeutics	$6.80	$6.41	-$0.39	$6.41	$802.13 million	$798.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
MNTA Momenta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.36	2.50	1.01
INCY Incyte	0.01	2.85	2.00
MNTA Momenta Pharmaceuticals	N/A	6.38	6.38
UTHR United Therapeutics	N/A	7.26	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
INCY Incyte	96.97%
MNTA Momenta Pharmaceuticals	N/A
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.18%
INCY Incyte	17.80%
MNTA Momenta Pharmaceuticals	3.40%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
INCY Incyte	2,617	195.28 million	159.12 million	Optionable
MNTA Momenta Pharmaceuticals	131	119.03 million	N/A	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

MNTA, BIIB, INCY, and UTHR Headlines

Recent News About These Companies

United Therapeutics Corporation (NASDAQ:UTHR) Short Interest Up 2,016.4% in July

1 hour ago | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Stock Price Up 4.9% - Here's Why

3 hours ago | marketbeat.com

Cantor Fitzgerald Analysts Lower Earnings Estimates for UTHR

August 2 at 6:23 AM | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by Natixis Advisors LLC

August 2 at 5:38 AM | marketbeat.com

3,108 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Purchased by GSA Capital Partners LLP

August 2 at 5:20 AM | marketbeat.com

United Therapeutics (UTHR) Launches $1 Billion Share Buyback

August 1 at 12:11 AM | gurufocus.com

United Therapeutics (NASDAQ:UTHR) Price Target Lowered to $295.00 at Wells Fargo & Company

August 1 at 1:05 PM | marketbeat.com

United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study

August 1 at 12:41 PM | tipranks.com

United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment

August 1 at 12:41 PM | tipranks.com

United Therapeutics enters $1B accelerated share repurchase program

August 1 at 8:21 AM | msn.com

Cozad Asset Management Inc. Acquires Shares of 1,805 United Therapeutics Corporation (NASDAQ:UTHR)

August 1 at 5:23 AM | marketbeat.com

Forecasting The Future: 8 Analyst Projections For United Therapeutics

July 31 at 4:16 PM | benzinga.com

UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y

July 31 at 11:16 AM | zacks.com

United Therapeutics (UTHR) Price Target Lowered by HC Wainwright & Co. | UTHR Stock News

July 31 at 8:12 AM | gurufocus.com

Optimistic Buy Rating for United Therapeutics Driven by Promising TETON Trial Prospects for Tyvaso in IPF Market

July 31 at 6:23 AM | tipranks.com

Earnings Summary on United Therapeutics

July 31 at 2:23 AM | fool.com

United Therapeutics Reports Record Q2 2025 Financial Results

July 30 at 12:31 AM | tipranks.com

United Therapeutics Corporation (UTHR) Q2 2025 Earnings Call Transcript

July 30 at 11:02 PM | seekingalpha.com

MannKind’s Growth Potential Bolstered by United Therapeutics Partnership and Promising Pipeline

July 30 at 3:50 PM | tipranks.com

United Therapeutics: Strong Growth Potential and Strategic Moves Justify Buy Rating

July 30 at 3:50 PM | tipranks.com

United Therapeutics Stock Slides On Q2 Earnings: The Details

July 30 at 3:33 PM | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNTA, BIIB, INCY, and UTHR Company Descriptions

Biogen NASDAQ:BIIB

$131.95 +3.95 (+3.09%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$132.24 +0.29 (+0.22%)

As of 08/1/2025 07:59 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Incyte NASDAQ:INCY

$75.59 +0.70 (+0.93%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$77.06 +1.47 (+1.95%)

As of 08/1/2025 07:47 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Momenta Pharmaceuticals NASDAQ:MNTA

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

United Therapeutics NASDAQ:UTHR

$294.28 +19.58 (+7.13%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$294.42 +0.15 (+0.05%)

As of 08/1/2025 07:26 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time